title: FDG-PET as a biomarker for early response in diffuse large B-cell lymphoma as well as in Hodgkin lymphoma? Ready for implementation in clinical practice?
authors: Department of Hematology, VU University medical center, Amsterdam, the Netherlands j.zijlstra@vumc.nl.
authors: Josée M
authors: JM
authors: Zijlstra
authors: Department of Hematology, VU University medical center, Amsterdam, the Netherlands.
authors: Coreline N
authors: CN
authors: Burggraaff
authors: Department of Hematology, Amsterdam Medical Center, the Netherlands.
authors: Marie José
authors: MJ
authors: Kersten
authors: Sally F
authors: SF
authors: Barrington
mesh_terms: D015415:Biomarkers / Q000032:analysis; D000068456:Clinical Studies as Topic; D019788:Fluorodeoxyglucose F18; D006689:Hodgkin Disease / Q000175:diagnosis* / Q000000981:diagnostic imaging; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000175:diagnosis* / Q000000981:diagnostic imaging; D049268:Positron-Emission Tomography / Q000379:methods*; D017410:Practice Guidelines as Topic; D011379:Prognosis
chemical_list: D015415:Biomarkers; D019788:Fluorodeoxyglucose F18